Farnesyl transferase inhibitors: Current developments and future perspectives

Cancer Treatment Reviews

Volumn 26, Issue 5, 2000, Pages 319-332

  Eskens, F A L M ^a   Stoter, G ^a   Verweij, J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Bisubstrate inhibitors; CAAX peptidomimetics; Clinical; Farnesyl transferase inhibitors; FPP analogues; Trials

Indexed keywords

1,2,3,4,9,9A HEXAHYDRO 2 [2 (2 METHOXYPHENYL) 1 OXO 2 PROPENYL] 9 (4 METHYLPHENYL) 4,9 ETHANO 3AH BENZ[F]ISOINDOLE 3A CARBOXYLIC ACID; 2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 (8 CHLORO 5,6 DIHYDRO 11H BENZO[5,6]CYCLOHEPTA[1,2 B]PYRIDIN 11 YLIDENE) 1 (4 PYRIDYLACETYL)PIPERIDINE; 5 [N [5 (2 BENZOXAZOLYL) 1 METHYL 2 [3,4 (METHYLENEDIOXY)PHENYL] 4 PENTENYL] N (2 NAPHTHYLMETHYL)CARBAMOYL] 1,3 DIOXOLANE 2,2,4 TRICARBOXYLIC ACID; A 197574; BENZO(F)PERHYDROISOINDOLE DERIVETIVE; BENZODIAZEPINE; BIM 46068; BMS 184467; BMS 185878; BMS 186511; CIFM TETRAPEPTIDE; CIIM TETRAPEPTIDE; CVFM TETRAPEPTIDE; FTI 2148; FTI 232; FTI 244; GERANYLTRANSFERASE; IRINOTECAN; L 731734; L 731735; L 778123; LONAFARNIB; MANUMYCIN; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE METHYL ESTER; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PD 169451; PHOSPHONIC ACID DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RPR 115135; SCH 59228; TETRAPEPTIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; CLINICAL TRIAL; CONFUSION; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; FATIGUE; GENE MUTATION; GROWTH INHIBITION; HUMAN; NEUROTOXICITY; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR REGRESSION; VERTIGO; VOMITING;

EID: 0033794603     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2000.0187     Document Type: Review

References (69)

1. Ras oncogenes in human cancer: A review
2. Ras C-terminal processing enzymes, new drug targets?
3. Farnesyl transferase inhibitors: Ras reseach yields a potential cancer therapeutic
4. Farnesyl transferase inhibitors and anti-Ras therapy
5. The potential of farnesyl transferase inhibitors as cancer chemotherapeutics
6. Function and regulation of Ras
7. Evidence that farnesyl transferase inhibitors suppress Ras transformation by interferring with Rho activity
8. Targeting farnesyl transferase: Is Ras relevant?
9. Identification of Ras farnesyl transferase inhibitors by microbial screening
10. Inhibitors of Ras farnesyltransferases
11. Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl protein transferase inhibitor
12. Growth inhibition of human pancreatic cancer by farnesyl transferase inhibitor
13. J-104,871, a novel farnesyl transferase inhibitor, blocks Ras farnesylation in vivo in a farnesylpyrophosophate-competitive manner
14. Synthesis and in-vitro structure-activity relationship of a new promising series of non peptidic protein farnesyl transferase inhibitors
15. Benzo[f]perhydroisoindoles: A series of potent and selective inhibitors of the farnesylation of Ki-Ras
16. Structure activity relationship and in vivo evaluation in a new promising family of nonpeptidomimetic farnesyl transferase inhibitors
17. RPR 130401, a non-peptidomimetic farnesyl transferase inhibitor with in vivo activity
18. In vivo combination of RPR 130401, a non-peptidomimetic farnesyl transferase inhibitor, with chemotherapy
19. In vivo evaluation of farnesyl transferase inhibitor PD 169451 versus a panel of human tumor xenografts
20. Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells
21. Benzodiaze pine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-ras transformed Rat-1 cells, but not in untransformed cells
22. Peptidomimetic inhibitors of Ras farnesylation, function in whole cells
23. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristilated oncogenic ras signaling and transformation
24. Inhibition of human tumor xenograft by treatment with the farnesyl transferase inhibitor B956
25. Anti tumor activity of farnesyl transferase inhibitor
26. Induction of parathyroid hormone-related peptide by the ras oncogene: Role of Ras farnesylation inhibitors as potential therapeutic agents for hypercalcemia of malignancy
27. Selective inhibition of Ras dependent transformation by a farnesyl transferase inibitor
28. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice
29. 2X competitive inhibitors of farnesyl transferase as anti-cancer agents
30. Farnesyltransferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment
31. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskelton
32. Evidence that farnesyl transferase inhibitors suppress Ras transformation by interfering with Rho activity
33. Non-Ras targets of farnesyl transferase inhibitors; focus on Rho
34. A peptidomimetic inhibitor of farnesyl protein transferase blocks the anchorage dependent and -independent growth of human tumor cell lines
35. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
36. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice
37. Treatment with farnesyl protein transferase inhibitor induces regressio of mammary tumors in transforming growth factor (TGF) α and TGF α/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis
38. The farnesyl transferase inhibitor L-744,832 inhibits the growth of astrocytomas through a combination of anti-proliferative, anti-angiogenic and pro-apoptotic activities
39. CaaX peptidomimetic FTI 244 decreases platelet-derived growth factor tyrosine phosphorylation levels and inhibits stimulation of phosphatidylinositol 3-kinase but not mitogen-activated protein kinase
40. Ras CAAX peptidomimetic FTI 276 blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation
41. Antitumor activity of non-thiol containing farnesyl transferase inhibitors
42. Chemotherapeutic effect of the farnesyl transferase inhibitor FTI-276 on 4-(methylnitrosarnino)-1-(3-pyridil)-1-butanone induced tumorigenesis in A/J mouse lung
43. Effective combination therapy with the non-thiol farnesyl transferase inhibitor FTI-2148 and taxol, gemcitabine or cisplatinum for human tumor xenografts in nude mice
44. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epithelones
45. Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells
46. Structure activity relationship of 3-substituted n-(pyridinylacetyl)-4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]py ridine-11-ylidene) -piperidine inhibitors of farnesyl protein transferase: Design and synthesis of in vivo active antitumor compounds
47. SCH 59228, a novel tricyclic inhibitor of farnesyl protein transferase, potently blocks the growth of Ras transformed fibroblasts and human tumor cell lines in nude mice
48. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice
49. SCH 66336, an orally bioavailable tricyclic farnesyl protein transferase inhibitor, demonstrates broad and potent in-vivo antitumor activity
50. Tumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase in human tumor xenograft models in wap-ras transgenic mice
51. Enhanced efficacy of the farnesyl protein transferase inhibitor SCH 66336 in combination with paclitaxel
52. R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI); biochemical and cellular effects in H-ras and K-ras dominent systems
53. R115777, a selectice farnesyl protein transferase inhibitor (FTI), induces predominantly apoptotic activity in C32 melanoma tumor xenografts
54. Interaction of the farnesyl protein transferase inhibitor (FTI) R115777 with cytotoxic chemotherapeutics in vitro and in vivo
55. Combined cell cycle and cytotoxic effects of paclitaxel and R115777, a specific inhibitor of p21 ras function and protein farnesylation in human prostate and breast carcinoma cell lines
56. Farnesyl diphosphate-based inhibitors of Ras farnesyl protein transferase
57. Phosphinyl-acid based bisubstrate analog inhibitors of Ras farnesyl protein transferase
58. Bisubstrate inhibitors of farnesyl transferase: A novel class of specific inhibitors of ras transformed cells
59. The farnesyl protein transferase (FPTase) inhibitor L-778,123 in patients with solid cancers
60. A phase I and pharmacologic study of the farnesyl protein transferase (FPT) inhibitor SCH 66336 in patients with locally advanced or metastatic cancer
61. Phase I and pharmacologic study of continuous daily oral SCH 66336, a novel farnesyl transferase inhibitor, in patients with solid tumors
62. Phase I and pharmacokinetic study of SCH 66336, a novel FPTI, using a 2-week on, 2-week off schedule
63. A clinical; pharmacodynamic and pharmacokinetic phase I study of SCH 66336 (SCH), an oral inhibitor of the enzyme farnesyl transferase, given once daily in patients with solid tumors
64. Phase I and pharmacokinetic study of farnesyl transferase inhibitor R1157777 in advanced cancer
65. Phase I clinical and pharmacokinetic trial of the farnesyl transferase inhibitor R115777 on a 21-day dosing schedule
66. Phase I and pharmacologic study with the novel farnesyl transferase inhibitor (FTI) R115777
67. Phase I combination trial of the farnesyl transferase inhibitor (FTI) R115777 with a 5FU/LV regimen in advanced colorectal and pancreatic cancer
68. The Ras signal transduction pathway
69. Ras protein farnesyl transferase: A strategic target for anticancer therapeutic development